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Chapter 3
Identification of MUC1 as a Potential Target for 
In-Vivo Imaging of Hilar Cholangiocarcinoma
H.T.J. Mantel, A.P.M. Matton, J.S. de Jong, P.J. van Diest, A.S.H. Gouw, 





Background: Hilar cholangiocarcinoma is an aggressive cancer with poor prognosis, largely 
due to its late presentation. The aim of this study was to identify potential targets for in vivo 
tumor-specific imaging of hilar cholangiocarcinoma using near-infrared light fluorescence 
(NIRF), which could potentially be applied to aid in tumor detection during cholangioscopy 
or during surgery. 
Methods: We performed a structured review of the literature to identify potential markers 
of hilar cholangiocarcinoma, using the previously established TArget Selection Criteria 
(TASC).  MUC1 emerged as the most promising marker and was subsequently tested 
immunohistochemically in 29 surgically resected hilar cholangiocarcinomas. 
Results: We found MUC1 expression of cholangiocarcinoma cells in 100% of cases, of which 
72% was classified as strong cytoplasmatic staining, 21% moderate cytoplasmatic, 3% weak 
cytoplasmatic, and 3% weak membranous. In 10% a mixture of both cytoplasmatic and 
membranous staining was observed. Non-malignant bile duct epithelial cells showed weak 
membranous staining in 67%, very weak membranous staining in 13%, weak-to-moderate in 
8%, and moderate staining in 4% (all on the luminal side only). Intermediate staining was 
noted in dysplastic and reactive biliary epithelial cells.
Conclusions: Using the TASC scoring system for a structured review of the literature we 
identified MUC1 as the most promising target for in vivo imaging of hilar cholangiocarcinoma. 
In a subsequent immunohistochemistry study, a clear difference was observed in MUC1 
expression between tumor and healthy biliary epithelial cells. These findings open new avenues 
for further development of an in vivo imaging tool for the detection of cholangiocarcinoma. 
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INTRODUCTION
Hilar cholangiocarcinoma (CCA), also known as a Klatskin tumor, is a malignant tumor arising 
from the biliary epithelium at or near the confluence of the right and left hepatic duct. It 
has the reputation of being difficult to diagnose and treat. Patients with unresectable disease 
have a poor prognosis of less than 6 months and die primarily from liver failure or infectious 
complications related to biliary obstruction1. 
Hilar CCA’s are usually adenocarcinomas (90%) and can be classified as mass-forming, 
intraductal growing or periductal infiltrating tumors2. Most hilar CCA’s belong to the latter 
type and have a specific growth pattern that is characterized by transmural invasion of the bile 
ducts with lymphatic, vascular and perineural infiltration. The tumors spread longitudinally 
along the submucosa of the bile ducts, causing diffuse thickening and obstruction of the 
lumen2,3.
Because of the absence of a focal mass, the tumors are often hard to depict by conventional 
radiology and the extent of the tumor is often underestimated4,5. Moreover hilar CCA’s 
frequently exhibit a dense desmoplastic (fibrotic) reaction, resulting in negative endoscopic 
brushings or biopsies even in the presence of well-established disease 6-8. 
The only potentially curative option is complete surgical resection of the tumor in 
combination with a partial liver resection. Five-year survival rates are between 11-40%3,9-11, 
reaching 35-43% when negative tumor margins are obtained10,12,13. However, due to the 
aforementioned growth characteristics of hilar CCA, it is often difficult for surgeons to obtain 
negative tumor margins3.
There is a need for earlier and more definitive diagnosis of hilar bile duct cancer to make 
more patients eligible for surgery. Since conventional radiology, endoscopy and laparoscopy 
fail to diagnose patients with early disease, there has been a shift in the focus of research 
towards near-infrared fluorescence (NIRF) tumor-targeted imaging. This rapidly evolving, 
experimental technique enables the specific visualization of tumor cells in vivo14 using a 
conjugate of a specific tumor target and a fluorophore, which fluoresces under near-infrared 
light. NIRF imaging would allow non-invasive diagnosis of bile duct cancer and monitoring 
of therapy effects and follow-up. Bile duct cancer is theoretically suited for molecular imaging 
because the tumor can be closely approached cholangioscopically. Furthermore, NIRF 
imaging could also be used for the real-time assessment of tumor margin negativity during 
surgery. In 2011, van Dam et al. were the first group to successfully perform intraoperative in 
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vivo imaging of ovarian cancer, using folate receptor- α as the tumor target 15.
 The ultimate goal is to develop an optical tracer that binds specifically to hilar CCA cells 
and emits photons in the near-infrared spectrum that can penetrate peritumoral tissue, 
reaching the cholangioscope. The first step in developing an optical tracer for hilar bile duct 
cancer is to select a suitable target. We have used the previously described scoring system 
based on TArget Selection Criteria (TASC) 16 to identify the most attractive potential marker 
for hilar CCA. In a subsequent immuonohistochemistry study of surgical resection specimens 
of patients with hilar CCA, we have evaluated the suitability of MUC1 as the most promising 
marker of hilar CCA.
 
MATERIALS AND METHODS
The Search For a Potential Hilar CCA Marker – TASC Scoring System
We used the paper by Briggs et al., 2009, a systematic review article that focuses on molecular 
biomarkers in CCA, as a basis for the identification of a potential NIRF marker for hilar CCA 17. 
We also included several other proteins that were described in the literature to be upregulated 
in hilar CCA. 
After initial identification, potential targets were rated according to the TASC (TArget 
Selection Criteria). The TASC scoring system16 is a method to identify potential cellular targets 
for molecular imaging. Each potential target can be scored on 7 items (Table 1). In the TASC 
system the extracellular location of the antigen is most important and therefore granted most 
points. A maximum of 22 points can be assigned and describes the ‘ideal’ target. An antigen 
that scores 18 or higher is considered a potential target and worth further investigation. 
Proteins that were not explicitly described in hilar or extrahepatic CCA were excluded from 
the analysis because intra- and extrahepatic CCA have different etiological and histological 
backgrounds. The antigen with the highest score and a clinically available antibody was then 
chosen to be immunohistochemically tested: MUC1.
Immunohistochemistry of MUC1 in Hilar CCA
Patient Selection
Twenty-nine patients who underwent surgery at the University Medical Center Groningen 
for hilar cholangiocarcinoma between May 2001 and July 2012 were selected. All patients 
underwent extrahepatic bile ducts resection with partial liver resection.
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Immunohistochemical Staining of Hilar CCA for MUC1
One block of each resected tumor, which are archived as paraffin blocks, was requested 
from the pathology department and paraffin section slides were cut at 3µm, placed on glass 
slides and left overnight in a 60°C stove. One slide of each tumor block was hematoxylin and 
eosin stained at the pathology lab, according to standard protocol. Immunohistochemical 
staining for MUC1 was performed using the automated staining machine (Bond TM System, 
Leica Microsystems GmbH, Wetzlar, Germany) and a biotin-free Bond TM Polymer Define 
Detection system (Leica Microsystems GmBH, Catalog no. DS98000).  After deparaffinization 
and rehydration, endogenous peroxidase activity was blocked for 5 min in a buffer solution 
pH5.8 containing 0.3% hydrogen peroxide. After antigen retrieval, which consisted of boiling 
in Tris/EDTA pH9.0 for 20 min, the sections were incubated with the primary MUC1 antibody 
(mouse monoclonal antibody, clone E29, Dako at 1:400) diluted in 1% BSA for 15 min. Slides 
were counterstaining with haematoxylin, dehydration in alcohol and mounting.
Scoring of Immunohistochemistry
All stainings were scored as 0: none, 1: weak, 2: moderate and 3: strong staining by one 
pathologist (JSJ) who was blinded to patient characteristics. 
Table 1. Target Selection Criteria Scoring System16
Characteristics Score
I Extracellular protein localization Bound to cell surface (receptor)
In close proximity of tumor cell
5
3
II Diffuse up-regulation through tumor tissue 4
III T/N ration >10 3








V Previously imaged with success in vivo 2
VI Enzymatic Activity 1
VII Internalization 1





The TASC for hilar CCA is shown in Table 2. MUC1 scored 20 points, followed by CD44 and 
MMP7. Unfortunately, the expression rates of these markers in hilar CCA have only been 
reported once.
Immunohistochemical Staining of hilar CCA for MUC1
Patient Demographics and Tumor Characteristics
Of the 29 patients with hilar CCA included in this study, 22 were male and 7 were female. The 
age at resection ranged from 44-76 years, with a mean age of 62.0 years. Table 3 shows the 
tumor characteristics of these 29 patients. The 6th edition of the TNM staging system was used 
to classify the tumors.
Immunohistochemistry for MUC1
The expression of MUC1 in tumor and in non-malignant cells is summarized in Table 4. There 
was MUC1 expression in all cases of hilar CCA (100%), of which 72% was strong cytoplasmatic 
(Figure 1), 21% moderate cytoplasmatic and 3% weak cytoplasmatic. Three cases showed 
both cytoplasmatic and membranous staining and one only weak membranous staining. 
Non-malignant bile ducts were found in 24 of the sections, of which 16 (67%) showed weak 
membranous staining (Figure 1), 3 (13%) very weak membranous staining, another 2 (8%) 
weak-to-moderate staining and 1 (4%) moderate staining (all on the luminal side only). 
Moderate staining of the membrane all around the cell occurred in only 2 (8%) cases in benign 
bile ducts and no cytoplasmatic staining of the benign bile ducts was seen. The stroma stained 
weakly positive for MUC1 in only one case, and the liver parenchyma and blood vessels were 
all negative. We observed a tendency for more dysplastic and reactive cells to stain more 
strongly than less dysplastic cells.
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Table 3. Tumor characteristics of 29 patients undergoing surgical resection of hilar cholangiocarcinoma
Variable Numbers




N stage N0 18
N1 11
Hepatic margin Positive 2
Negative 27
Bile duct margin Positive 9
Negative 20
PV/HA reconstruction due to tumor invasion Performed 6
Not performed 23




T: tumor, N: node, PV: portal vein, HA: hepatic artery








staining only on 
luminal side
Membranous staining all 
around the cell
Tumor 0 1/29   (3.4)* 25/29 (86.2)**
1 1/29   (3.4)* 1/29   (3.4)**
2 6/29   (20.6)* 1/29   (3.4)**
3 21/29 (72.4)* 2/29  (6.9)**
Non-malignant 
Bile Ducts
0 2/24   (8.3)† 22/24 (91.6)**
0-1 3/24   (12.5)† 0/24 (0.0)**
1 16/24 (66.6)† 0/24 (0.0)**
1-2 2/24   (8.3)† 0/24 (0.0)**
2 1/24   (4.2)† 2/24 (8.3)**
2-3 0/24   (0.0)† 0/24 (0.0)**
3 0/24   (0.0)† 0/24 (0.0)**
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DISCUSSION 
This study used the TASC scoring system 16 to search for a possible NIRF target for the in vivo 
imaging of hilar CCA. We found mucin 1, MUC1, to be the most promising target, scoring 
20 points. Mucins are a group of heavily glycosylated proteins produced by epithelial cells, 
forming a major component of mucus 55. MUC1 is expressed on the apical surface membrane 
Figure 1. Hematoxylin & eosin (HE) staining and immunohistochemistry for MUC1 of both malignant and 
non-malignant bile duct cells. Strong cytoplasmic expression of MUC1 (brown) is found in malignant cells 
(arrows), and weak luminal expression in non-malignant cells (arrowheads). Left column: HE staining (A: 
2x, C: 10x, E: 20x), right column MUC1 expression (B: 2x, D: 10x, F: 20x). (see color image on page 148)
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and an elevated expression has been associated with different types of cancer 56. We then 
immunohistochemically tested the expression of MUC1 in 29 resected hilar CCA specimens 
and found an expression rate of 100% in the tumor cells, of which 97% was cytoplasmatic 
(72% strong, 21% moderate and 3% weak) and 3% only weak membranous. 92% of non-
malignant bile duct cells showed membranous staining on the luminal side only, of which 67% 
was weak, and another 8% showed moderate cytoplasmatic staining. There was a tendency 
for non-malignant cholangiocytes to stain more strongly as the cells become more dysplastic 
and reactive.
Our results are comparable to those reported in literature. Expression rates of 72-100% 
in hilar or extrahepatic CCA have been reported 40-43, as well as absent expression in non-
neoplastic epithelium of the extrahepatic bile ducts 57. Sasaki et al.,1996 58, on the other 
hand, did report infrequent and focal MUC1 expression in 13% of normal livers. They also 
reported frequent and strong expression on the luminal surface of biliary epithelial cells of 
small bile ducts in 71% of patients with primary biliary cirrhosis and 75% of patients with 
chronic viral hepatitis, suggesting that biliary damage may also cause MUC1 upregulation. 
The non-malignant bile ducts that we examined were those of hilar CCA patients, where 
some biliary damage in the sense of congestion and hypoxia most likely also occurred. This is 
probably reflected in our observation that more reactive and dysplastic cells tended to stain 
more strongly for MUC1. Indeed, another study by Sasaki et al., 1996 40 also reported MUC1 
expression in biliary epithelial dysplasia in 29% of cases.
Nevertheless, we observed a distinct difference between the intense cytoplasmatic 
expression of MUC1 in cholangiocarcinoma compared to the weak luminal staining of the non-
tumorous bile ducts. Further experiments should assess whether this difference is enough to 
allow a significant “tumor-to-background ratio” at molecular in vivo imaging. On the other 
hand, as mentioned, we have reason to believe that even though MUC1 is a sensitive marker, 
it is perhaps not specific enough. This low specificity, however, can likely be explained by 
the fact that a broad and unspecific type of MUC1 antibody was used. There are subtypes of 
MUC1, and it has been found that an aberrantly or incompletely glycosylated type of MUC1 
is overexpressed in many tumor tissues, such as breast, stomach and colon cancers 59. This 
changes its biological behavior by interfering with cell adhesion and shielding the tumor cell 
from immune recognition, promoting metastasis 60. One study tested the expression of a novel 
humanized antibody specific to a tumor epitope of MUC1 (TA-MUC1), PankoMab-GEX™, in 
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ovarian cancer tissues 61. They found that PankoMab-GEX™ did not stain healthy ovarian 
tissue cancer, whereas other commonly used MUC1 antibodies (HMFG-1 and 115D8) did stain 
healthy ovarian tissue. We expect greater differences between malignant and non-malignant 
biliary epithelial cells when tumor-associated MUC1 antibodies are tested in hilar CCA, which 
will be the focus of our future research. Furthermore, PankoMab-GEX™ is a humanized 
antibody that is already in clinical trial, facilitating its potential use as a NIRF-target in the 
clinical setting.
In conclusion, using the TASC scoring system in search of a hilar CCA marker for NIRF 
imaging, we found MUC1 to be the most promising marker. We found a clear difference in 
MUC1 expression between tumor and healthy biliary epithelial cells. This is an encouraging 
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